ABA FTC v. Amgen/Horizon: New Theories in Action Webinar

• Life Sciences
• CRA Insights

Consequences of counterfeit pharmaceutical product sales

Recently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the...

• Intellectual Property
• Articles

Anticompetitive conduct and patents listed in the Orange Book

Branded pharmaceutical manufacturers are required by law to list all patents in the Orange Book that cover an approved drug product. However,...

• Damages & Quantum
• Speaking Engagement

• February 25, 2026
• Virtual

ABA Bundled Rebates: Dissecting the Regeneron Trial Webinar

Last year, Regeneron took to trial its case alleging exclusionary conduct through bundled rebates by competitor Amgen. The jury found for Regeneron, awarding...

• Life Sciences
• Sponsorship

• March 24, 2026
• Boston, MA

The Bravery Effect: Leverage the Science of Bravery to Elevate your Impact

CRA is a proud supporter of the Healthcare Businesswomen’s Association (HBA) and sponsor of the HBA Boston-Cambridge Metro chapter event hosting author and...